Moderna looks for full FDA endorsement for its COVID-19 vaccine Kumar Jeetendra | June 1, 2021 American pharmaceutical company Moderna says it has begun the process to win full U.S. regulatory approval for the use of its COVID-19 vaccine in adults. Moderna announced on Tuesday it has begun a “rolling submission” to the Food and Drug Administration of data from its studies of the two-dose vaccine. Moderna’s vaccine already has been …
Pfizer jabs delivers less antibodies against Delta variation of Covid: Lancet study Kumar Jeetendra | June 4, 2021 People fully vaccinated with the Pfizer-BioNTech vaccine are likely to have more than five times lower levels of neutralising antibodies against the Delta variant first identified in India compared to the original strain, according to research published in The Lancet journal. The study also shows that levels of these antibodies that are able to recognise …
India near offering reimbursement to foreign vaccine creators like Pfizer: Report Kumar Jeetendra | June 10, 2021 India is close to agreeing to grant foreign COVID-19 vaccine makers such as Pfizer Inc protection against legal liability so that it can use their shots in an immunisation campaign that is facing acute shortages, three government sources told Reuters. “Indemnity will be granted,” said one of the sources. “If one company gets it then …
Administrative gesture for conducting clinical trials of Colchicine on COVID-19 patients: CSIR Kumar Jeetendra | June 12, 2021 The Drugs Controller General of India (DCGI) has given approval to the CSIR and Laxai Life Sciences Private Limited to conduct clinical trial of Colchicine on COVID-19 patients, according to a statement on Saturday. Ram Vishwakarma, the advisor to the CSIR Director General, said Colchicine in combination with standard care will be an important therapeutic …
WHO chief Tedros Adhanom Ghebreyesus says vaccine need surpasses G7 vows Kumar Jeetendra | June 13, 2021 The head of the World Health Organisation has welcomed the vaccine-sharing announcements coming out of the Group of Seven summit but says “we need more, and we need them faster.” “The challenge, I said to the G-7 leaders, was that to truly end the pandemic, our goal must be to vaccinate at least 70% of …
Pfizer, AstraZeneca vaccines secure against Delta variant: Lancet study Kumar Jeetendra | June 15, 2021 The Delta variant of coronavirus, first identified in India, doubles the risk of hospitalisation compared with the Alpha variant first found in the UK, but Pfizer and AstraZeneca vaccines provide good protection against the strain, says a study published in The Lancet journal. Researchers at Public Health Scotland and the University of Edinburgh, UK, found …
AstraZeneca vaccine’s investigator backs India’s 12–16-week Covishield dose gap Kumar Jeetendra | June 19, 2021 Backing the 12-16 weeks gap between the two doses of Covishield in India, the chief investigator of the AstraZeneca vaccine clinical trials on June 18 said that the level of protection provided by one dose of the preventive significantly increases in the second and third months after the jab. In an interview with The Wire, …
Delta variant establishes more than 6% of tested COVID-19 cases with virus variant in NYC: Health division Kumar Jeetendra | June 19, 2021 The Delta variant, first detected in India, constituted over 6 per cent of COVID-19 cases tested for virus variants in New York City, according to official data from the city’s health department. The New York City Health Department said in its recent update that out of the 105 NYC COVID-19 cases tested for variant viruses …
China says one billion COVID-19 vaccine dosages administered Kumar Jeetendra | June 21, 2021 China said on June 20 that it has administered over one billion doses of COVID-19 vaccines in the country. China has accelerated its pace of free COVID-19 vaccinations for the whole nation since late March and administered a billion doses by June 19, the National Health Commission (NHC) said. The NHC, however, did not say …
AstraZeneca COVID-19 immunization connected to uncommon neurological disorder in India, UK Kumar Jeetendra | June 22, 2021 Eleven people who received the AstraZeneca-Oxford COVID-19 vaccine have developed a rare neurological disorder called Guillain-Barre syndrome, clinicians in India and England have reported in two separate studies. While seven cases were reported from a medical centre in Kerala, where about 1.2 million people were administered the AstraZeneca COVID-19 vaccine, known as Covishield in India, …
Pfizer, Moderna vaccines cut COVID-19 danger by 91%: Study Kumar Jeetendra | July 8, 2021 People who receive COVID-19 vaccines by Pfizer and Moderna are up to 91 per cent less likely to develop the disease, according to a US study which also suggests that the preventives reduce the severity of symptoms and duration in those who still get an infection. The research, published in the New England Journal of …
Coronavirus in all probability of natural not spilled from lab: Study Kumar Jeetendra | July 9, 2021 The SARS-CoV-2 virus, which causes COVID-19, most likely spread from an animal source to humans, and did not leak from a laboratory in Wuhan, China, according to a review of existing scientific evidence by a global team of scientists. The yet-to-be published study, posted on the pre-print server Zenodo on July 7, noted that while …
